{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:15:02Z","timestamp":1788052502333,"version":"build-2784847793"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119199","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:00:18Z","timestamp":1785697218000},"page":"119199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel cereblon-recruiting PRMT5 degraders with in vivo efficacy against triple-negative breast cancer"],"prefix":"10.1016","volume":"318","author":[{"given":"Yuzhan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhao","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiansen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceshi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119199_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119199_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119199_bib3","article-title":"Breast cancer organoids: a precision platform for modeling heterogeneity and advancing personalized therapy","volume":"1","author":"Yang","year":"2026","journal-title":"Mol Digit Med"},{"key":"10.1016\/j.ejmech.2026.119199_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119199_bib5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cancers12040916","article-title":"The landscape of targeted therapies in TNBC","volume":"12","author":"Vagia","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119199_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119199_bib7","article-title":"Cell-free DNA analysis for cancer management: technologies, features, and clinical translation","volume":"1","author":"Zhu","year":"2026","journal-title":"Mol Digit Med"},{"key":"10.1016\/j.ejmech.2026.119199_bib8","doi-asserted-by":"crossref","first-page":"17960","DOI":"10.1073\/pnas.1209814109","article-title":"Crystal structure of the human PRMT5:MEP50 complex","volume":"109","author":"Antonysamy","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119199_bib9","doi-asserted-by":"crossref","first-page":"20538","DOI":"10.1073\/pnas.1106946108","article-title":"Structural insights into protein arginine symmetric dimethylation by PRMT5","volume":"108","author":"Sun","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119199_bib10","doi-asserted-by":"crossref","first-page":"32321","DOI":"10.1074\/jbc.M109.043349","article-title":"The kruppel-like zinc finger protein ZNF224 recruits the arginine methyltransferase PRMT5 on the transcriptional repressor complex of the aldolase A gene","volume":"284","author":"Cesaro","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nsmb.1568","article-title":"PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing","volume":"16","author":"Zhao","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119199_bib12","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1016\/j.celrep.2017.11.096","article-title":"PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression","volume":"21","author":"Chiang","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119199_bib13","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1128\/MCB.24.21.9630-9645.2004","article-title":"Human SWI\/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of and tumor suppressor genes","volume":"24","author":"Pal","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119199_bib14","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/cvr\/cvad110","article-title":"Epigenetic regulation of vascular smooth muscle cell phenotypic switch and neointimal formation by PRMT5","volume":"119","author":"Zhu","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejmech.2026.119199_bib15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1128\/MCB.01528-06","article-title":"The protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin remodeling","volume":"27","author":"Dacwag","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119199_bib16","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1101\/gad.606110","article-title":"Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency","volume":"24","author":"Tee","year":"2010","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejmech.2026.119199_bib17","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119199_bib18","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1038\/s41418-021-00793-0","article-title":"Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119199_bib19","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1038\/ncomms9419","article-title":"Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis","volume":"6","author":"Hu","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119199_bib20","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/2159-8290.CD-20-0026","article-title":"PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2(V617F)-Mutant MPN","volume":"10","author":"Pastore","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119199_bib21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119199_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119199_bib23","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","article-title":"The regulation, functions and clinical relevance of arginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119199_bib24","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1021\/acs.jmedchem.8b00598","article-title":"Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib25","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/cam4.2114","article-title":"Protein arginine methyltransferase 5: a novel therapeutic target for triple-negative breast cancers","volume":"8","author":"Vinet","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2026.119199_bib26","doi-asserted-by":"crossref","first-page":"11106","DOI":"10.1093\/nar\/gkx727","article-title":"The PRMT5\/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer","volume":"45","author":"Rengasamy","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119199_bib27","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41467-021-23833-2","article-title":"PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis","volume":"12","author":"Yin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119199_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006890","article-title":"PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis","volume":"11","author":"Wang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2026.119199_bib29","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.chembiol.2024.08.003","article-title":"A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119199_bib30","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119199_bib31","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","article-title":"Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia","volume":"126","author":"Jin","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119199_bib32","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-Based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5*MTA complex for the treatment of MTAP-Deleted cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib33","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-Cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-Deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119199_bib34","doi-asserted-by":"crossref","first-page":"13604","DOI":"10.1021\/acs.jmedchem.4c00097","article-title":"Discovery and in vivo efficacy of AZ-PRMT5i-1, a novel PRMT5 inhibitor with high MTA cooperativity","volume":"67","author":"Smith","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib35","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/acs.jmedchem.4c03067","article-title":"Discovery of TNG462: a highly potent and selective MTA-Cooperative PRMT5 inhibitor to target cancers with MTAP deletion","volume":"68","author":"Cottrell","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib36","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1021\/acs.jmedchem.4c03101","article-title":"From DNA-Encoded Library screening to AM-9747: an MTA-Cooperative PRMT5 inhibitor with potent oral in vivo efficacy","volume":"68","author":"Sarvary","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib37","doi-asserted-by":"crossref","first-page":"18143","DOI":"10.1021\/acs.jmedchem.5c01895","article-title":"PRMT5: a promising synthetical lethal target for MTAP-Deleted cancers","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib38","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.molcel.2021.07.019","article-title":"Molecular basis for substrate recruitment to the PRMT5 methylosome","volume":"81","author":"Mulvaney","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119199_bib39","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1074\/jbc.M110.148486","article-title":"RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5), competes with pICln for binding and modulates PRMT5 complex composition and substrate specificity","volume":"286","author":"Guderian","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119199_bib41","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/onc.2016.287","article-title":"Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth","volume":"36","author":"Deng","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119199_bib42","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/s41375-019-0489-6","article-title":"PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K\/AKT in lymphoma cells","volume":"33","author":"Zhu","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119199_bib43","doi-asserted-by":"crossref","first-page":"14276","DOI":"10.1021\/acs.jmedchem.2c01159","article-title":"Blocking non-enzymatic functions by PROTAC-mediated targeted protein degradation","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib44","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425812122","article-title":"Discovery of an LSD1 PROTAC degrader","volume":"122","author":"Hosseini","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.119199_bib45","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1021\/acs.jmedchem.4c02021","article-title":"Monoselective histone deacetylase 6 PROTAC degrader shows tractability","volume":"68","author":"Garcha","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib46","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.apsb.2025.01.021","article-title":"Discovery of a potential hematologic malignancies therapy: selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function","volume":"15","author":"Jin","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119199_bib47","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1021\/acs.jmedchem.0c01111","article-title":"Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders","volume":"63","author":"Shen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib48","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1021\/acs.jmedchem.5c00198","article-title":"Discovery of a potent and selective protein arginine methyltransferase 5 (PRMT5) PROTAC degrader","volume":"68","author":"Zhong","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib49","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-024-03237-y","article-title":"Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer","volume":"43","author":"Guo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119199_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115444","article-title":"Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design","volume":"256","author":"Mi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib51","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/med.21877","article-title":"Strategies for designing proteolysis targeting chimaeras (PROTACs)","volume":"42","author":"He","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119199_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41570-025-00784-6","article-title":"Lessons learned in linking PROTACs from discovery to the clinic","volume":"10","author":"Pike","year":"2026","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.ejmech.2026.119199_bib53","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119199_bib54","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","article-title":"Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib55","doi-asserted-by":"crossref","first-page":"13852","DOI":"10.1021\/acs.jmedchem.4c00644","article-title":"Discovery of an exceptionally orally bioavailable and potent HPK1 PROTAC with enhancement of antitumor efficacy of anti-PD-L1 therapy","volume":"67","author":"Wu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116520","article-title":"Application and challenges of nitrogen heterocycles in PROTAC linker","volume":"273","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib57","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1021\/acs.jmedchem.1c00900","article-title":"Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer","volume":"64","author":"Xiang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib58","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1021\/acs.jmedchem.5c02858","article-title":"Discovery of XYD270 as a potent, selective, and orally efficacious BRD9 PROTAC for cancer therapy","volume":"69","author":"Huang","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib59","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","article-title":"Discovery of BWA-522, a first-in-class and orally bioavailable PROTAC degrader of the androgen receptor targeting N-Terminal domain for the treatment of prostate cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib60","doi-asserted-by":"crossref","first-page":"9120","DOI":"10.1021\/acs.jmedchem.1c00270","article-title":"Development of alectinib-based PROTACs as novel potent degraders of Anaplastic Lymphoma Kinase (ALK)","volume":"64","author":"Xie","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119199_bib61","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1021\/acs.jmedchem.4c01548","article-title":"Design, synthesis, and biological evaluation of 3,4-dihydroisoquinolin-1(2H)-one derivatives as protein arginine methyltransferase 5 inhibitors for the treatment of non-hodgkin's lymphoma","volume":"68","author":"Li","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:20:30Z","timestamp":1788049230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":61,"alternative-id":["S0223523426006446"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119199","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel cereblon-recruiting PRMT5 degraders with in vivo efficacy against triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119199"}}